Innovation Theater: Why the Most Impressive PBM in the Room Isn’t Always the Best One
Several years ago, I was consultant helping a client select a PBM. We invited three finalists.
The incumbent.
A hungry mid-sized PBM that checked most of the boxes.
And one of the industry’s giants.
The incumbent was running stale. The challenger was innovative, responsive, and aligned. The giant arrived with something else entirely. A production.
The Performance
The presentation was flawless. Beautiful dashboards. Custom reports. Sophisticated analytics. Clinical committees. Executive summaries. Roadmaps. Heat maps. Scorecards. Portal demos. Sound familiar?
Everything looked impressive. The room loved it. Especially the CFO. And that’s when I realized something: Most buyers don’t struggle to identify value. They struggle to separate value from theater.
The Bridge to Nowhere
As consultants, our job wasn’t to buy the most impressive presentation. It was to answer three questions:
Will it lower costs?
Will it improve outcomes?
Will it reduce friction?
Everything else was secondary. But that’s the danger of innovation theater. The dashboard becomes the product. The report becomes the strategy. The analytics become the outcome. A bridge gets built. It just doesn’t lead anywhere.
The Decision
The giant won. Not because the fundamentals were better. Because the presentation was. And no one ever gets fired for choosing “the giants.”
Against my recommendation. Against HR’s recommendation. The room fell in love with the performance. And the performance won… for about thirteen months.
The Sequel Nobody Wanted
Thirteen months later we were back in the same conference room. Different mood. Same people. Same discussion.
Costs hadn’t improved.
Outcomes hadn’t improved.
Friction hadn’t improved.
The dashboards were still beautiful. The reports were still impressive. The portal still worked exactly as advertised. And yet somehow nothing important had changed. When we pulled back the curtain, the answer was obvious.
The technology was new.
The model underneath wasn’t.
The incentives were the same.
The habits were the same.
The economics were the same.
It was a distinction without a difference.
And that’s a lesson the workers’ compensation industry keeps relearning. Innovation isn’t a portal. It isn’t a dashboard. It isn’t a report. It isn’t a prettier way to describe the same process.
Innovation is a measurable improvement in outcomes. Everything else is marketing.
The Real Test
This is becoming one of the defining questions in workers’ compensation pharmacy.
Not: Is this innovative? But: What exactly got better because of it?
Lower costs?
Better outcomes?
Less friction?
Faster recovery?
Better patient experience?
If the answer isn’t clear, it may not be innovation. It may be theater.
Curtain Call
You can put a new dashboard on an old model. You can redesign the reports. You can add AI, analytics, portals, committees, and buzzwords.
But eventually the curtain falls. And when it does, buyers are left with one question: What actually changed?
Because real innovation doesn’t always create a better presentation. But it consistently creates better results.
And in workers’ compensation pharmacy, the difference between the two is often measured in millions of dollars.
If you’re evaluating PBM innovation, start with the outcomes—not the performance. And If you’re tired of innovation theater, let’s talk.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
At Some Point, Results Matter More Than Relationships
One of the hardest leadership decisions isn’t identifying a failing partnership.
It’s admitting the partnership no longer deserves the benefit of the doubt.
I was talking with a colleague recently—let’s call her Elly—who was wrestling with exactly that.
Years ago, a vendor partner (“Jay”) had been exceptional. Her team loved him. The relationship was strong. The value was obvious. Problems got solved. Innovation happened. The partnership moved the business forward.
But over time, something changed.
Performance flattened. Meetings became repetitive. The same stale solutions kept reappearing in new PowerPoints. Response times slowed. Friction increased.
The relationship still felt familiar. It just no longer felt valuable.
Normally, this would be a straightforward business decision.
But Jay wasn’t just a vendor anymore. He was a trusted colleague. Someone Elly respected deeply. Someone who had earned goodwill over years of partnership.
And that was the problem.
Because once relationships become personal, leaders often stop measuring outcomes objectively. We start protecting history instead of evaluating performance.
That dynamic shows up quit a bit in workers’ comp pharmacy.
A PBM that “has always handled the account.”
A partner everyone is comfortable with.
A solution that once felt innovative… but hasn’t meaningfully evolved in years.
Meanwhile, the market keeps moving.
Specialty spend accelerates.
Transparency expectations rise.
Regulatory scrutiny increases.
Clinical complexity deepens.
But many buyers are still getting the same:
stale reporting
recycled clinical programs
opaque pricing logic
overcomplicated workflows
and innovation theater disguised as strategy
That’s the danger of trusting relationships more than results. Because familiarity has a way of masking decline.
Especially in PBM, where complexity can make mediocre performance look sophisticated.
And over time, the relationship itself becomes the justification.
Not the outcomes.
That’s the moment leaders need to pause. Because strong partners don’t ask you to ignore the scoreboard.
They want accountability.
They want transparency.
They want the results to speak for themselves.
The partnerships that struggle most with scrutiny are often the ones benefiting most from inertia.And inertia is expensive. Especially now.
The PBM market is entering a different era—one where buyers are starting to care less about legacy relationships and more about alignment, innovation, transparency, and measurable outcomes.
That shift matters. Because the question is no longer: “How long have we worked together?”
It’s becoming: “What are you doing today that meaningfully improves my program tomorrow?”
That’s a much harder question for stale partner to answer. Elly already knew what needed to happen.
That wasn’t the hard part.
The hard part was accepting that respect for someone’s past contribution does not obligate you to tolerate current underperformance.
That’s uncomfortable.
But it’s also leadership.
Because in the end, trust should reinforce results—not replace them.
And the moment trust starts asking you to ignore the outcomes…it may be time to trust the results instead.
And if you do, let’s connect.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
Staying Put: Your Most Expensive Non-Decision
Today’s post is about a decision most buyers don’t think they’re making.
Not choosing a new PBM. Not evaluating a new model. But something quieter: choosing not to switch.
Because in workers’ comp, staying put often feels like the safest move. It just doesn’t always turn out that way.
The Story We Tell Ourselves
When the idea of switching comes up, the same concerns surface:
“Adjusters will be disrupted.”
“We’ll create noise with injured workers.”
“We’ll have to retrain teams on a new portal.”
“We’ll lose reporting capabilities we rely on.”
It sounds responsible. Thoughtful, even.
But if you listen closely, most of these aren’t operational risks.
They’re assumptions that haven’t been re-underwritten in years.
The Switching Cost Fallacy
Here’s the quiet truth:
Most switching costs are overstated.
And most staying costs are understated.
Let’s break that down.
Adjuster Turmoil
The fear: “Adjusters won’t adapt. Productivity will dip.”
The reality: Adjusters adapt faster than systems give them credit for—especially when the workflow is cleaner.
What actually creates turmoil isn’t change.
It’s friction: manual workarounds, inconsistent approvals, unclear pricing logic
If those exist today, staying doesn’t eliminate disruption. It just makes it familiar.
Patient Noise
The fear: “Injured workers will feel the change.”
The reality: Patients feel breakdowns, not backend transitions.
Delays. Confusion. Access issues.
If the underlying model improves: faster fills, better coordination, clearer communication. Then the “noise” doesn’t increase. It decreases.
Portal Retraining
The fear: “We’ll have to retrain everyone.”
The reality: Most teams are already underutilizing what they have.
Be honest: How many features in your current system are: never used, poorly understood, or quietly ignored?
Retraining feels heavy… until you realize you’re often retraining around features no one relied on to begin with.
Reports and Capabilities
This is the big one.
The fear: “We’ll lose reporting.”
The reality: You won’t lose reporting.
You might lose reports that don’t drive decisions.
Dashboards that look sophisticated…but don’t change behavior.
Metrics that track activity…but don’t explain outcomes.
Over time, organizations accumulate reporting the same way they accumulate subscriptions: It’s there. It looks important. But no one would notice if it disappeared.
The Window Dressing Problem
This is where it all converges.
Switching costs are often built on: legacy workflows, unused tools, assumed dependencies, and “What if” scenarios.
It’s operational window dressing.
And it’s powerful—because it makes staying feel rational. Even when it isn’t.
What Doesn’t Get Measured
While all of this is being debated, something else is happening in parallel.
Quietly. Consistently.
Scripts routed through suboptimal channels
Pricing tied to benchmarks that don’t reflect reality
Specialty decisions made without full visibility
Leakage that never quite triggers a red flag
Nothing breaks. But nothing optimizes either.
And over time, that gap compounds.
The Real Cost Curve
Switching has a cost. No one disputes that.
But it’s: Finite. Time-bound. Visible
Staying has a cost too. It’s just: Recurring. Compounding. Hidden in the baseline
One is a line item. The other is a curve.
A Simple Reframe
Instead of asking:
“Can we afford to switch?”Ask something more precise.
Ask Yourself This: What is the true cost of switching?
Not the assumed version.
Not the inherited narrative.
The true cost:
Of retraining
Of transition
Of short-term disruption
Then compare it—honestly—to the cost of:
Another year of suboptimal routing
Another cycle of opaque pricing
Another set of reports that don’t drive action
You might find something uncomfortable.
It may be costing you more to stay put than to move.
Final Thought
In workers’ comp, inertia doesn’t feel like a decision. But it is.
And like most decisions in this space, it compounds.
If you need to rethink your switching costs, let’s get started.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
The Network Effect That Broke Trust
Most payers don’t stay with a PBM because they’ve re-underwritten the model. They stay because everyone else has. That’s the network effect. And for a long time, it worked.
What It Was Supposed to Do
Simple idea: More users = more value. In pharmacy, that became scale. More reach. More data. More leverage.
So buyers assumed:
If everyone is using the same PBM, pricing improves, access expands, outcomes follow. They didn’t just choose a PBM. They joined a network.
When Scale Became Assumption
Then something changed. The network stopped being evaluated…and started being inherited.
“This is who we’ve always used.”
“This is who everyone else uses.”
“Switching would be disruptive.”
That’s how network effects deepen. Not through proof — through assumption. And assumption creates something dangerous: permission to stop asking questions.
When Trust Became Leverage
Here’s where it breaks. Network effects only work if trust holds. If it doesn’t, scale stops creating value—and starts creating leverage.
That leverage shows up in ways payers don’t always see:
Benchmarks that can be engineered
Discounts applied to inflated prices
Clinical rules that aren’t applied consistently
Revenue tied to complexity
Systems that are hard to verify
None of it is obvious. That’s the point. The same network that created confidence…made it harder to question what was underneath.
The Signal Is Clear
Payers are starting to feel it.
A majority of payers report dissatisfaction
Net Promoter Scores sit in the single digits
Outcomes haven’t kept pace with complexity
That’s not a pricing issue. It’s a trust issue. And when trust breaks, network effects don’t protect you. They expose you.
Why Buyers Stay
Because networks don’t just create value. They create inertia.
Contracts are embedded
Systems are integrated
Teams are trained around the model
Leaving feels like disruption. So payers stay longer than they should. Not because it’s working — but because it’s easier.
The Shift
A different kind of network is forming. Not built on size. Built on alignment. The questions are changing:
Can I see how pricing is built?
Are incentives aligned with outcomes?
Does the model reward cost—or care?
Can I verify this without a translator?
That’s the new network. Built on transparency, trust, and alignment. And it’s growing - on trust, and the network follows.
The Counter-Network
You don’t break a network effect by attacking it. You break it by building a better one. One where:
Transparency replaces complexity
Alignment replaces arbitrage
Patients sit at the center
Pricing reflects reality
Trust is earned—not assumed
That’s where the momentum is shifting. And it gives payers something they haven’t had in a long time: permission to unlearn—and delink from the networks that took your trust for granted. You’re Not Stuck. You’re connected. And connections can change.
The Question That Matters
Stop asking: “Is this market competitive?”
Start asking: “Does this network deserve my trust?”
Because network effects don’t just amplify scale. They amplify intent. And the next network will be built by the buyers who decide to verify again.
If you need to rethink your current network, let’s get started.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
Trust, But Verify: Why “Market Competitive Pricing” Tells You Nothing
Today’s post starts with a principle every fiduciary knows but not everyone follows: Trust, but verify.
In workers’ comp pharmacy, that principle matters most when your PBM say “your pricing is market competitive.” It sounds reassuring, even analytical, like someone has done the math.
But in today’s PBM environment, that phrase often tells you less than you think — and sometimes nothing at all. Because many payers are still fighting yesterday’s war, using yesterday’s metrics, against a pricing model that has already moved on.
And when the battlefield changes, trust alone isn’t enough. You have to verify. You Must!
The War Buyers Think They’re Fighting
For years, pharmacy contracts were judged by a familiar checklist:
Bigger discounts off AWP
Tighter prior authorization rules
More utilization edits
More clinical criteria
More reporting
More portals
More workflow
The assumption was simple:
If the discounts are deeper and the controls are tighter, the program must be better.
And for a long time, buyers trusted that logic.
But trust only works when the underlying system is honest.
When pricing itself becomes engineered, the old scorecard stops working — and “market competitive” becomes a phrase you should verify, not accept.
The Illusion of the Discount
One of the oldest tricks in PBM pricing is also the easiest to miss.
Raise the starting price high enough…
and you can offer any discount you want.
Investigations over the past several years — including federal cases involving large PBMs and their affiliated pharmacies — have shown examples where:
Average Wholesale Prices (AWPs) were inflated by over 1000%
The PBM then applied a “discount”
The payer was told they were receiving market-leading pricing
On paper, everything looked competitive.
In reality, the price was still far above what the drug actually cost.
This is exactly where trust but verify matters.
Because if the benchmark itself is distorted, comparing discounts inside that benchmark tells you nothing. You can trust the report. You can trust the contract. You can trust the dashboard.
But if you never verify how the price was built, you may be trusting the illusion.
When Clinical Rules Apply… Except When They Don’t
Another place where buyers often rely on trust is clinical oversight.
Prior authorizations
Step therapy
Quantity limits
High-level review committees
Clinical leadership teams
Complex approval workflows
All of it sounds like protection. And sometimes it is. But in multiple cases — including issues raised in recent federal litigation — PBMs have been accused of:
Enforcing strict criteria at outside pharmacies
Relaxing or bypassing criteria when prescriptions ran through pharmacies they owned
Steering volume internally where prices were higher
From the outside, the payer still saw: strong clinical programs, detailed reporting, sophisticated portals, “market competitive pricing,” everything looked controlled, and everything looked verified.
But the incentives underneath were never aligned. That’s the problem when the system depends on trust without transparency. You don’t notice the difference until the cost shows up.
Complexity Can Look Like Control
Modern PBM programs often come with everything you would expect from a sophisticated platform:
Real-time dashboards and custom reporting portals
Performance metrics, fee schedules and rebate guarantees
Clinical reviews and specialty pathways
Workflow approvals, exception tracking and network tiers
It feels advanced. It feels like oversight. It feels like someone is watching everything. And buyers naturally trust that more complexity means more control. But complexity can also make verification harder.
The more layers there are between the prescription and the price,
the easier it becomes to hide how the money actually moves.
That’s why “market competitive pricing” is not a verification. It’s a description. And descriptions are easy to engineer.
Payers (Buyers) Are Still Fighting Yesterday’s War
Most RFPs still ask the same questions they asked ten years ago: what is your AWP discount? What is your rebate guarantee? What are your clinical edits? How does your network compare to the market?
Those questions assume the game is about percentages. The current game is about structure. It’s about: who sets the starting price, who owns the pharmacy, who keeps the spread, who controls the data, who decides when rules apply, and who benefits when the drug costs more.
If those incentives aren’t aligned, no discount can fix it.
You can trust the contract. You can trust the guarantees. You can trust the presentation. But if you never verify the model, you may still lose.
The Market Is Starting to Verify
You can see the shift happening. Recent FTC actions against large PBMs and their affiliated entities have focused less on discounts — and more on structure:
Pharmacy steering
Rebate arrangements
Conflicts of interest
Lack of transparency in how prices are set
The details will continue to play out. But the signal is clear. The conversation is moving awayfrom: How big is the discount?
and toward: How does the model actually make money?
That’s the question buyers should have been verifying all along. Because fiduciary responsibility isn’t about trusting the system. It’s about making sure the system deserves trust.
Occam’s Razor for PBM Pricing
There’s a principle in science called Occam’s Razor.
The simplest explanation is usually the right one.
In pharmacy pricing, that principle works surprisingly well.
If the model requires:
Ten portals
Five committees
Three pricing formulas
Two rebate reconciliations
And a 40-page contract
…just to understand how the PBM gets paid, then the answer probably isn’t simple. And if the answer isn’t simple, it probably isn’t aligned.
So here’s the verification test.
Ask your PBM one question:
In ten words or less, how do you make money on my program?
If the answer is clear, direct, and easy to explain, your pricing might actually mean something.
If the answer requires a presentation… Then “market competitive” probably isn’t verification. It’s just trust. And in today’s PBM market, trust without verification is the most expensive mistake you can make.
As I’ve said before, clarity is no longer optional. It is the rule. If you still cannot get clarity from your PBM, that’s where I come in. Contact me, I’m here to help.
— DEL
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
What the FTC Settlement Really Reveals About PBM Math
When the Federal Trade Commission reached its settlement with Express Scripts, many headlines focused on rebates. But that wasn’t the real story.
The FTC didn’t outlaw rebates. It targeted the economic machinery that makes opaque rebate-driven models work. And for workers’ compensation buyers, that distinction matters.
What the Order Actually Constrained
The settlement addressed practices that have quietly shaped PBM economics for years:
Spread pricing layered into pharmacy reimbursement
Steering toward higher list-price (high-WAC) versions
Compensation tied to list price rather than net cost
Delayed or opaque rebate reconciliation
Undisclosed broker compensation structures
These are not theoretical concerns. They are revenue strategies. And when revenue strategies rely on list-price inflation and opacity, the payer absorbs risk without seeing it.
Why This Hits Workers’ Comp Harder
In commercial health, rebate distortion often shows up in member out-of-pocket cost. In workers’ compensation, it shows up somewhere else:
Inflated AWP benchmarks
Specialty creep without clinical discipline
Channel steering toward owned pharmacies
Delayed true-ups that distort fiscal-year budgeting
“Net guarantees” that mask unit price inflation
Workers’ comp buyers often hear: “It’s built into your pricing.”
But pricing without transparent inputs is self-calculated.
And when the PBM controls:
The benchmark reference
The dispensing channel
The formulary
The rebate contracts
The reporting cadence
That’s the architecture the FTC just put under a microscope.
The High-WAC Lever
One of the quietest and most powerful PBM levers has been high-WAC arbitrage. Higher list prices create the appearance of larger savings. But if the starting price is inflated, the rebate is stabilization — not value creation.
Therefore, when regulators target steering and list-price distortion, that lever weakens. And when that lever weakens, PBM margins compress, and payers benefit.
This Settlement Isn’t About One PBM
This settlement is not about one company. It is about a model built on:
Opaque spread
Rebate arbitrage
Vertical steering
Compensation opacity
The FTC didn’t say rebates are illegal. It signaled that rebate-dependent opacity is regulatory risk. That is a structural indictment.
Ask Your PBM This
If you are responsible for public funds or employer capital in workers’ comp, ask directly: if rebates disappeared tomorrow, would your pricing model still hold up?
If the answer requires caveats, disclaimers, or delayed reporting, rebates aren’t the problem. Opacity is.
The Workers’ Comp Reality
Workers’ comp is smaller than commercial health. It has less leverage. It often inherits contracting logic from the broader PBM ecosystem. Which means when regulatory gravity shifts in commercial markets, workers’ comp eventually absorbs the shock or enjoy the benefits.
The prudent move isn’t to wait. It’s to align now with models that don’t depend on fog.
Executive Bottom Line
While the FTC didn’t attack rebates, it attacked: spread pricing, list-price distortion, steering practices and compensation opacity.
For workers’ comp fiduciaries, the message is simple:
If your PBM model requires opacity to stabilize margin, that is structural risk.
And structural risk eventually becomes financial exposure.
Clarity is no longer optional. It is direction of travel.
If you still cannot get clarity from your PBM, contact me, I’m here to help.
— DEL
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
PBM Math 101: Where the Money Actually Moves
Let’s start with a simple truth:
Most PBM conversations sound like math…
but feel suspiciously like magic tricks.
Lots of numbers.
Lots of percentages.
Lots of confident pointing at slides.
Very little clarity about where the money actually goes.
That’s not an accident. That’s fuzzy logic at work.
The Math Everyone Is Taught to Watch
In workers’ comp, we’re trained to focus on:
AWP discounts
Network penetration
“Fee schedule savings”
It’s familiar. Reassuring. Easy to repeat in a meeting.
It’s also the wrong math.
Because PBMs don’t really make their money on the sticker price.
They make it on what happens after the prescription is filled.
Where Things Get… Fuzzy
In earlier P4Ps, we talked about doing the right math.
This is where that idea stops being philosophical.
We’ve seen — and written about — cases where AWPs on drugs dispensed through PBM-owned pharmacies were inflated dramatically. In some instances, not by a few points… but by multiples of actual acquisition cost.
Think about that for a second.
Same drug. Same pharmacy. Same corporate family. Just a very flexible definition of “average wholesale price.”
That’s not market forces. That’s math being gently nudged until it behaves.
Why Ownership Changes Everything
When a PBM also owns the pharmacy, something subtle but powerful happens.
The system can:
Influence the benchmark
Route the prescription
Capture the spread
All inside the same house.
On paper, the employer still sees a “discount.”
In reality, the baseline quietly moved.
It’s like marking up the price of a couch 5x…
then proudly offering 40% off.
Technically accurate.
Practically misleading.
This Is Why Prosecutors Eventually Get Curious
This isn’t just a theoretical problem. It’s a historical one.
Federal indictments in the PBM and pharmacy space didn’t come from misunderstanding complex math. They came from patterns:
Inflated pricing references
Self-dealing through affiliated pharmacies
Misrepresentation of actual drug costs
Not overnight scandals — slow-burn models that worked too well.
Fuzzy logic scales beautifully… right up until it doesn’t.
Incentives Always Win (Even Over Good Intentions)
Most people in these systems aren’t villains.
But incentives don’t need bad actors to misbehave.
If revenue improves when:
Prices drift upward
Certain drugs are preferred
Prescriptions stay “in network” internally
Then the math will quietly follow the incentive.
You don’t get the outcomes you hope for.
You get the outcomes the math rewards.
The Prodigy Difference: Calm Math, Clean Lines
At Prodigy, we take a pretty boring — but powerful — approach:
If you can’t trace the dollar, we don’t like the model.
That means:
No inflated benchmarks hiding behind discounts
No spread that only shows up if you squint
No benefit to higher prices
When acquisition cost goes down, clients win.
When it goes up, you can see why.
It’s not flashy math.
It’s just honest math.
One Question Worth Asking
If you want to know whether your PBM uses fuzzy logic or real math, try this:
“Can you show me how AWP is set for drugs dispensed through your own pharmacies — and how that compares to what the drug actually costs?”
Not a summary. Not a blended number. Just the comparison.
Clear models answer calmly.
Fuzzy ones suddenly have a lot to say.
The Real Lesson of PBM Math 101
PBM math isn’t complicated. It’s selective.
And in workers’ comp — where payers don’t see receipts and patients don’t choose therapies — selectivity adds up fast.
The next generation of TPAs, risk managers, and leaders won’t win by negotiating harder.
They’ll win by:
Doing the right math
Asking better questions
Choosing partners whose models still make sense in daylight
Because when the math is clean, trust comes easy.
And when the math is fuzzy…someone eventually brings a flashlight.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
Why Transparent Pricing Still Feels So Rare in Workers’ Comp
Transparent pricing in workers’ comp is widely praised—almost universally, in fact. Yet when it comes time to choose it, most buyers hesitate.
Not because transparency is unproven.
Not because it doesn’t work.
But because the system has trained smart, rational leaders to be careful in ways that quietly preserve the status quo.
Opacity didn’t win in workers’ comp by being superior.
It won by being familiar.
The Comfort of “Good Enough”
Most pricing models persist because they function. Claims get paid. Networks stay intact. Reports get delivered. No alarms go off.
That absence of friction becomes its own form of validation.
Over time, “working” is confused with “working well.” And when no single stakeholder owns the full economic picture—drug cost, clinical impact, administrative drag—there’s little pressure to interrogate the model beneath the surface.
Complacency doesn’t announce itself. It blends in as professionalism.
Prudence, or Fear Wearing a Suit?
Buyers are trained to manage risk. And from that vantage point, sticking with a known PBM model can feel like the responsible choice.
Switching introduces questions:
Will this disrupt claims flow?
Will providers push back?
Will something break—and land on my desk?
These are reasonable concerns. But prudence becomes counterproductive when it only evaluates what could go wrong—and not what is already quietly going wrong.
Fear of change in workers’ comp rarely looks emotional. It looks analytical. It shows up as spreadsheets that model transition costs but ignore structural leakage.
The Switching Cost Mirage
One of the most powerful forces keeping opaque pricing in place is the belief that switching is expensive and disruptive. Sometimes it is.
But more often, buyers overestimate the one-time cost of change and underestimate the recurring cost of staying put.
What rarely gets quantified:
Time spent reconciling unclear invoices
Clinical decisions made without full cost visibility
Savings narratives that can’t be independently verified
These costs don’t arrive as a single invoice. They compound quietly—spread across departments, renewals, and years.
Opacity is not free. It’s just well-disguised.
The Benefits We Discount
Transparent pricing doesn’t just clarify what you pay. It clarifies how decisions get made.
When pricing is explicit:
Clinical conversations sharpen
Accountability increases
Reporting becomes usable, not ceremonial
But these downstream benefits don’t always show up in year-one ROI calculations. They show up in governance, trust, and speed of decision-making.
Systems built to minimize disruption tend to discount benefits that arrive later—even when those benefits fundamentally change how the organization operates.
Why Transparency Feels Risky (and Why It Isn’t)
Transparency feels disruptive because it removes ambiguity—and ambiguity has been doing a lot of quiet work.
It cushions difficult conversations.
It spreads responsibility thin enough that no one feels fully exposed.
It allows “net savings” to substitute for verifiable math.
But when pricing is truly transparent, something unexpected happens: complexity decreases.
Fewer explanations are needed.
Fewer exceptions are negotiated.
Fewer assumptions are carried forward unchallenged.
Organizations that move toward transparent PBM models don’t experience chaos—they experience compression. Decisions get faster because the facts are visible.
This is where solutions like Prodigy differentiate quietly but meaningfully—not by promising perfection, but by removing the fog that forces buyers to operate on trust alone.
Ask Yourself
If transparent pricing is so clearly aligned with fiduciary responsibility, the real question isn’t why it’s rare.
It’s this:
Which risks are you actively managing—and which ones have you simply grown used to?
Are you protecting your organization from disruption, or from clarity?
And if you had full visibility tomorrow, which decisions would you make differently?
Transparent pricing doesn’t demand recklessness. It demands honesty.
And in workers’ comp, honesty isn’t radical—it’s overdue.
The prescription for performance isn’t bravado. It’s the discipline to see clearly—and the prudence to act on it. Get in touch, let’s talk.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
The Top 3 Comp Pharmacy Trends That Will Actually Matter in 2026
P4P #1 — Resetting the Board for 2026
Every year starts with predictions. Most of them are polite. Most of them are safe. Most of them age poorly.
This isn’t that.
This is Prescription for Performance #1 for 2026—written for leaders who actually have to make decisions, explain them, and live with the downstream consequences.
If 2024 and 2025 were about awareness, 2026 is about enforcement—by regulators, by cities, and increasingly by buyers themselves.
Here are the three trends that will define comp pharmacy this year, whether the industry is ready or not.
1. Transparency Is No Longer Optional—and It Can’t Be Retrofitted
Let’s start with the obvious one—because it’s no longer theoretical. Transparency is now being demanded, enforced, and litigated.
Federal lawsuits against the largest PBMs have pulled back the curtain on unfair pricing, rebate games, and conflicted incentives. At the same time, cities and public entities are passing their own transparency and audit requirements, forcing PBMs to explain—not just report—how money actually moves.
Here’s the part the industry doesn’t like to say out loud:
You can’t bolt transparency onto a business model that depends on opacity.
The largest PBMs were not designed for clarity.
They were designed for scale, leverage, and complexity.
And complexity is a terrible place to hide when:
Regulators are asking second and third questions
Cities want audit rights written into contracts
Public buyers have to defend decisions in open meetings
This is why transparency initiatives from legacy incumbents often feel performative:
More dashboards
More reports
More “trust us” language
But very little structural change.
PBMs built differently—like Prodigy—don’t have to retrofit transparency. It’s native to the model. When incentives are aligned and economics are straightforward, transparency isn’t a risk—it’s a strength.
2026 reality: Transparency is no longer a differentiator. It’s a gate. And some PBMs simply won’t fit through it.
2. Specialty Drugs Are the Fastest-Growing Force in Workers’ Comp—and Discounts Won’t Save You.
Specialty drugs are no longer “emerging” in workers’ comp. They’re here—and accelerating.
Driven by:
A robust FDA specialty pipeline
Expanded presumptive coverage laws
Increased use of biologics, injectables, and infused therapies
Specialty is now the fastest-growing segment of comp pharmacy spend. And yet, many strategies still revolve around one tired idea: “Can we get a better discount?”
That mindset misses the point.
In workers’ comp, specialty cost isn’t driven primarily by unit price. It’s driven by:
Clinical appropriateness
Timing of care
Site of care
Duration of care
Whether the therapy actually matches the condition
We’ve already covered this in prior P4P articles—certain specialty drugs and conditions consistently drive outsized claim impact. The lesson hasn’t changed, but the stakes have.
The winning strategy in 2026 goes beyond discounts and asks:
Moving from transaction review to clinical pathway design
Shifting focus from “Is this allowed?” to “Is this appropriate now?”
Treating specialty as a care strategy, not a billing anomaly
This is where models like Specialty Nexus matter—not just as a carve-out, but as an operating layer that brings clinical governance to specialty spend.
2026 reality: If your specialty strategy stops at pricing, you don’t have a strategy—you have exposure.
3. The PBM Model Itself Is Under Scrutiny—and Fiduciary Discipline Is the New Standard.
At this point, every PBM should have gotten the memo. This is the hardest conversation—and the most important.
The traditional PBM model is being questioned not because it’s unpopular, but because it’s indefensible under scrutiny.
For years, the industry normalized practices that would never survive a fiduciary lens:
Wonky pricing hidden behind “network guarantees”
Rebates disconnected from clinical decisions
Formularies influenced by economics no one wants to explain
As prior P4P articles have called out: these aren’t edge cases. They’re structural features of legacy PBM design.
In 2026, that matters—because buyers are changing how they evaluate partners. The new questions sound like:
Who is this PBM actually working for?
Where do incentives sit?
Can this model withstand an audit, a regulator, or a public hearing?
PBMs like Prodigy that operate with fiduciary discipline, clean economics, and explicit controls don’t fear these questions. They welcome them. Others will spend the year managing narratives instead of outcomes.
2026 reality: The PBM model is no longer judged by promised savings—but by whether it can survive daylight.
The Throughline for 2026
These aren’t three separate trends. They’re one story.
Transparency pressures expose weak models.
Specialty growth amplifies clinical risk.
And legacy PBM economics struggle to justify under scrutiny.
2026 will reward leaders who:
Choose partners built for scrutiny, not scale alone
Treat specialty as a clinical challenge, not a pricing exercise
Demand fiduciary clarity instead of accepting industry norms
The comp pharmacy system isn’t collapsing. It’s being forced to grow up.
And as always, performance follows design.
Transparency isn’t coming—it’s here. Specialty isn’t slowing. And PBM models are being tested in public. In 2026, leaders will design outcomes. Everyone else will explain them. Let’s schedule time to plan your 2026.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
Transparency Theatre
For years, the industry treated transparency like theatre—an applause line, not a business model. Some PBMs dimmed the lights, shuffled a few set pieces, and insisted the stage had changed.
But the audience isn’t buying it anymore.
Workers’ comp payers are asking harder questions.
New delivery models are emerging.
Payers are being forced to do more with less, even as cost, complexity, and clinical risk accelerate.
And underneath it all, a truth the industry has tried to outrun is finally catching up:
You can’t retrofit transparency into a PBM business model built on secrecy and opacity.
The economics don’t work. The workflows don’t align. And the technology simply wasn’t designed for the world that now exists.
The Industry’s Strategic Moment
This isn’t a wake-up call. It’s a restructuring of the entire ecosystem.
Employers want pharmacy program designs that actually work for their injured workers—not the illusion of choice inside a locked box.
Workers’ comp payers want treatment pathways that reduce friction, improve return-to-work, and eliminate unnecessary spend.
Meanwhile, incumbents keep trying to repaint the walls of a house sinking into its own foundation.
Gaslighting payers cannot solve this. Transformation can.
We Built Prodigy for This Moment
Prodigy wasn’t built to survive the old world.
Prodigy was built to replace it.
While others built on the status quo, we chased architectural readiness.
While others relied on rebates to fill margin gaps, we built a model where value creation didn’t require hiding the true cost of care behind a curtain.
And while legacy PBMs stitched together siloed workflows to promote opacity, we designed unified process—with real-time visibility that unlocks:
Smarter and faster decision-making
Seamless patient experience
Payer flexibility and customization
True transparency
It’s what employers have needed.
It’s what payers have been waiting for.
And it’s what legacy systems simply cannot retrofit into their DNA.
This isn’t speculation. It’s design. The status quo was never going to carry the industry into its next era.
The Market Has Spoken
The next decade will be defined by leaders who embrace three truths:
Transparency is not a feature—it is a foundation.
You cannot layer it onto a model architected for opacity.
Anything less is a costly delay tactic.Fiduciary responsibility is no longer optional.
Payers can’t outsource judgment to vendors with misaligned economics and incentives.Care only works when the patient is the center of gravity.
The moment the system forgets that, costs rise, outcomes fall, and friction multiplies. Put the patient first, and everything else finally falls into place.
The payers that evolve will succeed. Everyone else will see mediocre outcomes or worse.
If you’re shaping your 2025–2026 strategy, here’s what leaders are doing next:
Rebuilding pharmacy programs around transparency + intelligence
Moving aways from PBMs with business models dependent over-reliant on rebate-driven economics.
Prioritizing systems that lower friction for adjusters, nurses, and members
Partnering with platforms/partners (like Prodigy) designed for transformation—not preservation
If you’re ready to move beyond transparency theater, and would like to explore what this transition looks like for your organization, I’d be happy to help you map it.
The market is moving. The question is who’s moving with it. Let’s schedule time to experience full transparency at scale.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
Why Big PBMs Can’t Offer Transparency at Scale
You can’t retrofit transparency into a PBM business model built on secrecy and opacity.
Trying to retrofit transparency into a legacy PBM is like bolting windows onto a submarine—at best, you get a brief view; at worst, you sink the vessel.
Transparency sounds simple, but it is operationally incompatible with business models built on opacity. Everyone wants the credit for being “open,” yet few can afford what openness really costs.
The Transparency Paradox
Large PBMs—and several mid-market ones—publicly praise transparency while their financials depend on keeping it partial. The contradiction is structural: these entities are publicly traded, with earnings expectations tied to rebate retention, spread pricing, and network differentials.
According to industry filings, retained rebates (including PBM GPO and data access fees) and spreads represent 25–40% of gross margins for the top three PBMs (GAO, 2024; SEC, 2023). Those margins are not side effects; they are the business model. Full transparency would flatten those profits and immediately hit forward-looking earnings—something no public PBM management can tolerate.
The result is what we at Prodigy call the Transparency Theater: partial disclosures, selective data access, and clever contract language that implies honesty while preserving the status quo.
Cultural and Operational Inertia
Transparency isn’t a software toggle—it’s a cultural rewiring. It demands changing how people are trained, how systems are built, and how incentives are paid.
Legacy PBMs reward teams for maximizing retained revenue; their infrastructure was engineered for opacity. You can’t ask an organization to show all its cards when the dealer’s bonus depends on what stays hidden.
Why Scale Breaks Transparency
Transparency doesn’t scale when your infrastructure profits from confusion.
Real transparency requires synchronized data across claims, rebates, and network contracts—essentially a real-time, audit-ready ledger. For a billion-claim processor, that’s not a modernization effort; it’s an existential threat.
Prodigy’s Embedded Transparency
At Prodigy, transparency isn’t a retrofit—it’s the foundation. It’s a core part of our ethos — in words, in action and in software code. Transparency is part of our operating system for trust—built so every claim, rebate, and fee is visible in real time. No tiers of visibility. No selective disclosure. No “trust us” clauses. Our clients see exactly what we see—because trust scales only when visibility does.
Our Challenge to the Industry
Transparency cannot be modularized. You can’t graft integrity onto infrastructure optimized for arbitrage.
Ask your PBM one question:
Would your transparency survive an independent audit—without excuses, redactions, or NDAs?
Real transparency doesn’t need stage lights. It needs courage, clean code, and a culture that doesn’t flinch when the curtains lift. We built Prodigy to do just that — make transparency operational, not aspirational. Because when visibility is native, accountability becomes second nature.
If you’re ready to move beyond transparency theater, we’d love to show you what real visibility looks like in practice. Let’s schedule a short demo to experience full transparency at scale.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
3 Excuses PBMs Use to Keep Your Rebates — And Why They’re Bogus
The cost of drugs has become America’s quiet scandal—skyrocketing expenses wrapped in layers of complexity that only benefit those controlling the middle. As state and federal regulators tighten the vise on transparency, one truth keeps surfacing: rebates are the soft underbelly of the PBM model. They were meant to lower costs, but for many payers, they’ve become the black box where savings disappear. The irony? The data exists, the dollars exist, and the excuses don’t hold up under daylight..
Excuse #1: “They’re Baked Into Your Pricing.”
It sounds neat, logical—even generous. Your PBM claims you’re already benefiting from rebates through lower upfront drug costs or discounted AWP. But peel back the label, and you’ll find that “baked in” means you’re paying for the ingredients, but someone else is eating the cake.
Key Point: “If rebates were truly baked into pricing, every PBM’s price should rise and fall with the manufacturer’s rebate cycle. They don’t.”
At Prodigy, we’ve tested this myth. Over and over, we’ve provided equal or better pricing and passed rebates back to our clients. The numbers don’t lie—rebates can coexist with competitive rates when transparency is real. When they’re not, someone’s pocketing the spread.
Excuse #2: “Rebates Are Hard to Reconcile Back to Your Claims.”
Here’s the PBM equivalent of the “it’s complicated” relationship status. They’ll tell you the timing doesn’t align: the claim might be closed, the patient stopped taking the medication, or the reconciliation could create extra administrative work. Quite convenient.
Key Point: “Complexity is the oldest refuge of the unaccountable. Don’t settle for mediocre.”
Every system is designed to produce the exact result it produces. If rebates are slow, opaque, and hard to match back to claims, that’s not an accident—it’s by design. The status quo benefits the PBM, not the payer. At Prodigy, we rewired the system to do what it should do: trace every dollar, align timing, and make reporting as clean as the claim itself.
Excuse #3: “Rebates Don’t Exist—Or They’re Too Small to Matter.”
This one’s almost impressive in its audacity. PBMs argue that rebates are negligible, or don’t apply to your formulary mix. The reality? Most brand drugs—specialty or not—generate rebates. Federal and state laws reference them. Even the White House has taken aim at rebate opacity through executive orders.
Key Point: “When someone tells you rebates don’t exist, ask them why laws keep being written about them.”
Across our clients, rebates often represent hundreds of thousands of recoverable dollars annually—money that can fund better patient programs, technology investments, or direct cost savings. Saying they’re negligible is like saying gravity is optional. You can ignore it, but it’s still pulling on your wallet.
The Simple Truth
When you strip away the excuses, the logic circles back to one clean answer:
“Occam’s Razor: the simplest explanation is that they’re keeping them.”
If rebates don’t flow to you, they flow somewhere. PBMs have built an infrastructure that normalizes opacity under the guise of convenience. But make no mistake—what’s convenient for them is costly for you.
Rewiring the System
At Prodigy, we designed our model around radical transparency. We don’t bury rebates under pricing, defer them in reconciliation purgatory, or pretend they don’t exist. We show them. We share them. We make them make sense. Because in a system that’s been designed to obscure, clarity is the most disruptive act of all.
If your PBM can’t show you exactly where your rebates go, you already know the answer. It’s time to stop accepting complexity as destiny.
Prodigy is rewiring the entire system—one honest dollar at a time. Don’t let your PBM spin the story—”Rebates” and “Competitive Price” are not mutually exclusive.
If you’re ready to take action, let’s talk. Let us benchmark your program—category by category—and show you exactly what you should be getting back.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Drug Rebates: The Money You’re Leaving on the Table
Imagine buying a new car and the dealer quietly pockets the manufacturer’s rebate instead of passing it to you. And you are stuck paying full price (MSRP) for the car. Yikes. That’s exactly what’s happening in pharmacy benefits when your PBM keeps rebates—or worse, tells you the rebates are “already baked into the price.”
Here’s the truth: if you’re not receiving rebates, you’re not just being left behind—you may be getting taken advantage of.
Prodigy has proven time and again that we can deliver competitive—or better—pricing while also disclosing and sharing rebates from manufacturers. Rebates aren’t a side perk; they are a core source of savings, especially on high-cost and specialty drugs.
Where Rebates Really Live
The myth in workers’ compensation is that rebates are rare. The reality? Most brand drugs—specialty or not—are eligible for rebates. Let’s spotlight a few categories straight from our rebate data:
Oncology (Cancer Therapies): Drugs like Keytruda (immunotherapy) and Abraxane (chemotherapy) often carry meaningful rebates, even though they sit at the top of your spend chart.
Hematology & Blood Disorders: Products for sickle cell disease and hemophilia may look like “must-pay, no-choice” categories—but rebates exist here too.
Ophthalmology: Eye-care drugs for diabetic macular edema and dry eye disease come with rebate opportunities most payers never see.
Dermatology: From alopecia treatments to blockbuster biologics like Olumiant, dermatology has become a hidden rebate minefield.
Mental Health & Women’s Health: Even drugs for substance use disorder (Sublocade, Vivitrol) and contraceptives (Mirena, Kyleena) can be rebatable.
This isn’t theory. These are real, category-wide rebate dollars flowing through the system. If you’re not seeing them, ask yourself—where are they going?
Don’t Just Take Our Word for It
Rebates aren’t some Prodigy invention. State laws across the country and even a presidential executive order on drug pricing have specifically targeted rebate transparency. Why? Because regulators know it’s one of the biggest pressure points in pharmacy costs.
If lawmakers think it’s worth policing, shouldn’t payers make sure they’re not missing out?
The Easy Decision
Rebates shouldn’t be controversial. They’re your dollars, generated by your claims. You deserve to see them, measure them, and keep them.
At Prodigy, we don’t play the “baked into pricing” shell game. We give you competitive or better pricing AND your rebates—in some cases, every penny.
Final Word
If you’re not receiving rebates, you are getting left behind. Don’t let your PBM spin the story—”Rebates” and “Competitive Price” are not mutually exclusive. In today’s market, this isn’t a “nice to have.” It’s a performance must-have.
If you’re ready to take action, let’s talk. Let us benchmark your program—category by category—and show you exactly what you should be getting back.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Reconnecting With Your Why.
The Forgotten Why
In workers’ comp, it’s easy to get caught up in the mechanics: claims in, bills out, discounts tracked, reports generated. But if that’s all your PBM is doing, they’re missing the mark. Pharmacy benefits aren’t about transactions—they’re about people. Injured workers. Patients trying to get their lives back. Families depending on a system that often feels like a maze. Your team in the front lines making all of this work.
Too many PBMs have turned the job into a commodity, measuring success by how many fills they can process or how quickly a claim gets paid. That’s not a “why.” That’s a “what.” And when your PBM’s “what” isn’t connected to your “why,” you’re left with misalignment, waste, and frustration.
Finding Your Why
Your “why” is the anchor. For claims executives and risk managers, it’s not just about savings. It’s about ensuring the right medication, at the right time, for the right reason—without unnecessary friction.
When you start with your “why”:
The who becomes clear—partners that share your values rise to the top.
The what becomes sharper—programs, controls, and clinical oversight are no longer abstract; they’re purposeful.
The future becomes possible—because you’re no longer measuring success by transaction volume but by patient recovery and systemic clarity.
The PBM That Serves Your Why
The PBM that serves your why isn’t a claims processor. It’s a guidepost back to your purpose.
From billing to belonging: Moving past “discounts and deals” into true alignment with payer goals.
From opaque to open: Transparent pricing and clinical clarity that reconnect decisions to outcomes.
From reactive to reflective: Instead of chasing problems, designing programs that reduce complexity before it starts.
At Prodigy, our “why” is simple: to help patients recover faster, safer, and smarter—while giving payers clarity and confidence in a space known for confusion and equivocation. We exist to make the process simpler, the outcomes stronger, and the noise disappear.
A Final Word
If your PBM doesn’t connect you to your “why,” then you don’t have a partner—you have a vendor. And if you can’t articulate your “why,” then it’s time to pause, rethink, and realign.
Because when you know your why, the who and the what become clear.
If you’re ready to realign your PBM with your purpose, let’s talk. Prodigy helps payers and claims leaders rediscover their why—and turn it into measurable outcomes.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Summer Postcards from the Edge of the PBM World
Vacation mode: activated. Strategic thinking: still on.
Even when you step away from the screen and slow down, the world has a way of whispering lessons—if you're listening. On a recent getaway, between good food and better sunsets, I couldn’t help but notice how everyday moments mirrored the very things we talk about in workers’ comp pharmacy management.
So instead of skipping this edition of P4P entirely, I’m sending you a few strategic postcards from the road. Each one is a bite-sized reminder of the traps to avoid—and the clarity that still wins.
🏖️ Postcard #1 – From the Beach: The Illusion of “All-Inclusive”
“Lying on a resort beach that promised ‘all-inclusive’—except for chairs, towels, drinks, and the air I breathe. Sound familiar? Legacy PBMs love this game. Always read the fine print.”
We’ve all been sold the dream. But when the real cost shows up on the bill, the promise fades. If your PBM says “all-in,” ask what they’re leaving out.
🏞️ Postcard #2 – From the Mountains: Path Dependency
“We saw hikers blindly follow each other up the wrong trail. Made me think of payers sticking with the ‘safe’ PBM path—only to find the view (and value) disappointing.”
Comfort is a poor substitute for strategy. Just because a path is worn doesn’t mean it leads somewhere worthwhile.
🍷 Postcard #3 – From Wine Country: Brand Loyalty Blindness
“Tourists dropping $200 on a wine just because of the label. Back home, payers do the same with PBMs. If the performance is average, the brand premium is just waste.”
A fancy label doesn’t make it a better vintage. In pharmacy benefit management, brand trust should be earned—not assumed.
🛍️ Postcard #4 – From the Markets: Wolves in Sheep’s Clothing
“Every booth claimed ‘authentic local goods’—until I saw the same barcode stickers from Amazon. Lesson: flashy doesn’t mean real. A reminder for evaluating vendors, too.”
There’s a growing trend of lookalike PBMs using transparency language while hiding legacy behaviors. Scrutinize what’s under the hood.
📸 Postcard #5 – From a Tour Bus: The Cost of Comfort
“Most tourists chose the bus tour. Easier, familiar, no thinking required. But they missed the best spots. Same with pharmacy networks—comfort is expensive. Custom beats cookie-cutter.”
Customization doesn’t mean complexity—it means better outcomes. Don’t pay for ease. Pay for value.
Back Soon. But Here’s What I’ll Leave You With.
Sometimes, distance brings clarity. Whether you’re rethinking your PBM, prepping for renewals, or just trying to make smarter decisions in a noisy market—don’t wait for perfect timing. Clarity compounds.
I'll be back with new P4P insights in two weeks. Until then, if anything here hits home, drop me a note or forward this to someone who’s still drinking the brand-label wine.
Better decisions start with better questions.
Let’s ask smarter ones—together.
—Del
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Field Notes from the Frontline: 3 Pharmacy Pains Payers Can’t Ignore
Over the past few weeks, we’ve been in deep conversations with TPAs, carriers, and self-insured employers—and a pattern has emerged. Everyone’s wrestling with some version of the same headache:
→ GLP-1s sneaking into claims
→ Physician dispensing bypassing oversight
→ And PBM “transparency” that feels anything but clear.
In this week’s P4P, we’re cutting through the noise. No fluff, no spin—just the top 3 pharmacy pain points facing workers’ comp payers right now, and smarter ways to fix them.
Because when the fog clears, so does performance.
⸻
1. GLP-1s Are the Canary in the Coal Mine
Once a whisper, now a roar—GLP-1s like Ozempic and Wegovy are flooding into comp claims, often without supporting documentation, outcomes monitoring, or long-term cost plans. They’re not the only specialty drug making noise—but they’re a warning shot.
✅ The Fix:
Layer in pre-approval checkpoints for high-cost therapies. Build a clinical approval framework that doesn’t just say yes or no—but asks why, when, and for how long. Combine that with longitudinal monitoring to stop passive approvals from becoming long-term liabilities.
2. Physician Dispensing Sidesteps the Playbook
Despite formulary rules and networks, physician dispensing remains a costly loophole. It inflates spend, undermines safeguards, and often escapes audit trails.
✅ The Fix:
Deploy real-time clinical edits with custom business rules—ones that flag physician-dispensed meds automatically for review or rejection. Partner with your PBM to maintain a strict default posture grounded in statute. It’s not about policing—it’s about protecting.
3. Transparency Talk, Vendor Walk
Many payers still don’t know what they’re actually paying for—or where the dollars go. Rebate math is fuzzy. AWP discounts are inflated. “Pass-through” often passes over critical context.
✅ The Fix:
Move beyond buzzwords. Demand line-item clarity on pricing, rebate logic, and service fees. Require MAC list visibility. Push for contracts with auditable definitions—not vague assurances. If a PBM can’t show you exactly how it makes money, you’re the product.
Final Dose
Most of the challenges in workers’ comp pharmacy aren’t unsolvable—they’re just untreated. Payers don’t need a new strategy. They need a true partner who can see the red flags before the bill hits the system and tailor solutions to fit their risk, population, and workflow. That’s what Prodigy was built for.
Better decisions start with better questions.
Let’s ask smarter ones—together.
📞 Let’s talk. If you’re ready to trade volume for value, and autopilot for actual oversight, Prodigy is ready to show you what real care looks like. Call me for a virtual consult. No pressure. Just clarity. I promise—it’ll be worth your while.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
PBM Mirage
When Volume Poses as Value
Let’s call it what it is.
For too many PBMs, “pharmacy benefit management” has become a misnomer. They don’t manage pharmacy benefits—they manage fills. They don’t guide care—they automate approvals. And the endgame isn’t better outcomes—it’s faster fills, higher volume, and margin on the move.
It’s not care. It’s commerce—disguised in acronyms.
This is the fill-and-bill industrial complex, where injured workers become units of throughput, and clinical nuance is paved over by protocols written to prioritize profit.
At Prodigy, we’ve seen it up close:
Formularies that push brand-name drugs with rebates, not outcomes
Mail order programs that reward speed over scrutiny
“Clinical programs” that are just glorified prior auth queues
Meanwhile, patients with polypharmacy risks, behavioral health flags, or complex comorbidities are run through templated workflows—zeroing out what actually matters: clinical intervention.
At Prodigy, we do it differently:
✅ Our pharmacists aren’t hidden behind policies—they’re embedded in every complex case
✅ We flag risky combinations and step in early—before costs explode
✅ We call physicians directly, provide evidence-based alternatives, and track outcomes post-intervention
✅ We don't just audit prescriptions—we own clinical performance
Because the real job isn’t filling scripts—it’s preventing the wrong ones, adjusting the risky ones, and advocating for what’s best for the patient.
Here are three ways to tell if your PBM is just pushing pills under the guise of management:
Do they intervene—or just authorize?
If clinical review takes less time than brewing coffee, it’s not review. It’s rubber-stamping.Do you know which patients were actually helped?
Or just how many were processed?Do your pharmacists lead—or follow the script?
Because if tech teams are setting your clinical policy, don’t expect care—expect compliance theater.
Pharmacy benefit management isn’t about throughput. It’s about thoughtfulness, helping payers and improving patient outcomes.
📞 Let’s talk. If you’re ready to trade volume for value, and autopilot for actual oversight, Prodigy is ready to show you what real care looks like. Call me for a virtual consult. No pressure. Just clarity. I promise—it’ll be worth your while.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Brand Loyalty or Blind Faith?
Familiar Names. Hidden Risks.
We get it. The big names feel safe. They’ve been around forever. You know the reps. The deck looks good. The reports feel “familiar.”
But let’s be blunt—familiarity is not protection. In the PBM world, it’s often the perfect camouflage.
The big three PBMs? They're not just legacy players—they're legacy liabilities. They’re currently under federal investigation. They’ve been linked to executive orders targeting drug pricing practices. And yet, many payers keep renewing—often on autopilot—because the brand feels easier than the unknown.
That ease comes at a cost.
Behind the brand loyalty, we’ve seen:
Contracts built a decade ago still quietly driving decisions
Formularies bloated with margin-fattening drugs
Spread pricing embedded in layers of complexity
"Custom reports" that show exactly what they want you to see—and nothing more
Here’s the risk no one talks about: sticking with legacy logos can expose you to scrutiny—scrutiny you didn’t invite but may be forced to answer for. When your PBM ends up in the headlines, what’s your defense?
Three ways to test if your “trusted” partner is quietly eroding trust:
Would you pick them again if starting fresh today?
If not, you’re paying the nostalgia tax.Does your pricing model still hold up under scrutiny?
Or is it just a pile of spreadsheets and handshakes?Is your PBM aligned to your goals—or just leveraging your loyalty?
When things go wrong, do they act like a partner or a PR firm?
At Prodigy, we’ve helped payers carve out of these relationships without chaos. No fire, no fury—just a smarter hedge that reduces risk and restores control.
Because in this market, brand loyalty isn’t just expensive—it’s dangerous.
Ask yourself:
Is your PBM implicated—directly or indirectly—in investigations around pricing abuse or their role in the opioid epidemic?
(Hint: If they’re one of the Big Three, the answer may already be yes.)
Are you getting the same level of service, access, and strategic attention as their biggest book of business?
Or are you just a line item behind a firewall of policy?Do you feel like a third wheel—locked in a lopsided relationship you can’t seem to shake?
If so, ask yourself: who’s really benefiting from your loyalty?
📞 Let’s talk. There’s a smarter way forward—and it starts with asking better questions. Call me for a virtual consult. No pressure. Just clarity. I promise—it’ll be worth your while.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Wolves in Sheep’s Clothing
Transparency Talkers, Accountability Dodgers
Isn’t it rich? The same PBMs that spent years pillaging payer budgets now parade around as prophets of transparency—shouting “clarity” from the rooftops like they just discovered sunlight.
But beware the rebrand. Today’s PBM landscape is full of “transparency” models that are anything but. There are shades of openness, gradients of clarity, and just enough polish to pass as progress.
Here’s the truth: some PBMs have learned to talk the talk, but what they’re offering is a distinction without a difference. The costume has changed, but the playbook hasn’t.
So how do you know if your PBM is just putting on a show?
Here are three tests to separate the real from the rehearsed:
Do you know—really know—your true program costs?
Not averages. Not anecdotes. Actual, all-in, claim-by-claim cost visibility.Do you have access to raw, unfiltered data?
Not scrubbed reports or dashboards designed for optics. The truth is in the raw feed.Is your PBM acting like a real partner—or a vendor with a thesaurus?
Do they solve problems or just explain them away?
— ALWAYS READ THE FINE PRINT!
Forget the glossy portals and the polished pitch decks. At Prodigy, we believe transparency isn't something you perform—it’s something you prove.
We put our stake in the ground. Whether it’s turnaround time, clinical outreach, financial guarantees, or real-time reporting, we build accountability into every contract with SLAs and performance guarantees. No fluff. Just stakes, skin, and standards.
Ask yourself:
Does your PBM have skin in the game?
Can you hold them accountable in writing?
Are you actually satisfied with the status quo?
If you hesitated—or said no—to any of these, it might be time to explore a smarter alternative.
📞 Call me for a virtual consult. No pressure. Just clarity.
I promise—it’ll be worth your while.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO Del, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management.
No fluff. No spin. Just insight that pays off.
Hedge Your Bet, Don’t Burn the Bridge
April is over and Q2 is now in full swing.
You’re back in rhythm. Revisiting old conversations. Following up on open loops. Asking your team the question you tabled weeks ago: “How’s our PBM doing?”
The answer? It’s not chaos. But it’s not confidence either.
The numbers aren’t glaring. The outcomes aren’t awful. But the updates come with a raised eyebrow, a hesitant “well…”—the kind of feedback that doesn’t ring alarms but still lingers in the gut.
You’re not regretting the decision. But you are re-evaluating the bet.
The Quiet Dilemma
As an executive, you were instrumental in selecting your PBM or ancillary partner. You did the diligence. You saw the deck. And at the time, the hand looked promising.
But leadership isn’t about making the perfect call—it’s about knowing when to adjust before the table turns cold.
That’s where hedging comes in.
Hedging isn’t a panic play. It’s a proactive posture.
It’s not walking away—it’s widening the aperture. Think of it as trimming the hedges while the garden still looks good. You’re not replacing the foundation; you’re reinforcing the fault lines.
At Prodigy, this is our specialty. Clients don’t have to ditch their PBMs—they carve out the riskiest, costliest corners:
Specialty medications that account for 1-2% of scripts but 20%+ of total drug spend
Catastrophic claims where oversight matters most
Challenging geographies with spotty vendor performance
These areas get moved into our clinically-driven model—with real-time reviews, evidence-based protocols, and unmatched specialty insight—while your traditional meds stay right where they are.
You stay in control. You gain visibility.
And most importantly—you stay ahead.
Hedging, Done Right, Does Three Things:
1. Protects Without Provoking
Why gamble on a full transition when you can surgically target the outliers? Specialty carve-outs let you pressure-test smarter models without unnecessary friction.
2. Reveals What’s Really Under the Hood
You know what your PBM reports. But what are they missing? Our team applies 50+ clinical and claims endpoints to identify misaligned drugs, wasteful dosing, off-label drift, and hidden high-cost risks.
3. Keeps You in the Driver’s Seat
Hedging gives you leverage without litigation. It nudges your incumbent to improve while giving you a runway to build a smarter model over time.
So if Q2 has you sensing some slippage—or if your gut says “we can do better”—you’re not alone.
You don’t have to start from scratch.
You just have to start hedging with purpose.
Bottom Line:
Not ready to replace your PBM? No problem. You can hedge your bet by carving out high-risk, high-cost areas—like specialty drugs or catastrophic claims—without disrupting your entire program. Prodigy helps clients layer in clinical precision where it matters most, giving you more control, better oversight, and real savings—without rolling the dice.
Let’s talk. We’ll help you turn second thoughts into first-mover advantage.